RxDoctor Payments Data

Esteban Figueroa, MD

Gastroenterology · Charlottesville, VANPI 1114345246

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $59,063 of the $65,996 with a category attached, or 89.5%. AbbVie accounts for 82.3% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $52,596, more than ten times the $117 reported in 2021. Among gastroenterology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$65,996in general payments, 2019–2025

Across 54 payments — averaging $1222.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$54K
  • Johnson & Johnson$11K
  • Bristol Myers Squibb$249
$173,252in research payments, 2019–2025

Across 82 payments — averaging $2112.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$173K

What the payments were for

  • Speaking & faculty fees$59,06389%
  • Travel & lodging$4,7857%
  • Food & beverage$2,1493%

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie45$54,313
Johnson & Johnson7$11,434
Bristol Myers Squibb2$249

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,996 in reported general payments places this provider in the 95th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$74,829
Medicare patients
332
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab48$1,394,475
Skyrizi On-BodyRisankizumab-Rzaa17$345,773
Mesalamine33$22,898
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl42$557
Pantoprazole Sodium19$243
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl12$224
Ondansetron OdtOndansetron12$178
Prednisone16$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$11,434$1,394,47548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →